Stock Runners: Calix, Inc. (NYSE:CALX), CVS Health Corporation (NYSE:CVS)

The fund owned 1,703,764 shares of the pharmacy operator's stock after buying an additional 247,875 shares during the period. BP PLC raised its position in CVS Health Corporation by 17.9% in the second quarter.

CVS Health Corporation closed its last trading session at $79.41 with the gain of 0.05%. The Company serves employers, insurance companies, unions, government employee groups, managed care organizations and other sponsors of health benefit plans, and individuals under the CVS Caremark Pharmacy Services, Caremark, CVS Caremark, CarePlus CVS/pharmacy, RxAmerica, Accordant, SilverScript, and Novologix names. Following the transaction, the President and CEO is left with a stake of 973,258 shares, now valued at $77325348. Bridge Creek Capital Management LLC now owns 39,538 shares of the pharmacy operator's stock valued at $3,785,000 after buying an additional 179 shares during the period. Independent Advisor Alliance acquired a new position in shares of CVS Health Corporation during the fourth quarter worth about $2,023,000. Gemmer Asset Management LLC now owns 1,409 shares of the pharmacy operator's stock valued at $125,000 after buying an additional 100 shares during the period. Canada Pension Plan Investment Board boosted its position in CVS Health Corporation by 101.7% in the third quarter.

A number of analysts offered their Estimated Earnings analysis for CVS Health Corporation (NYSE:CVS) for the current quarter. Finally, Veritas Asset Management LLP raised its position in CVS Health Corporation by 10.1% in the second quarter. Looking at the stock's movement on the chart, CVS Health Corporation recorded a 52-week high of $105.04. During the same quarter in the previous year, the company posted $1.53 EPS. The pharmacy operator reported $1.71 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.67 by $0.04. The mean revenue estimate for the current fiscal period ending December 2016 is $1.27B by 12 brokerage firms. The return on equity ratio or ROE stands at 53.3 percent while most common profitability ratio return on investment (ROI) was 5.7 percent. During the same quarter in the prior year, the company earned $1.28 earnings per share.

Several sell side analysts reviewed their recommendations on CVS Health Corporation (NYSE:CVS) where 8 analyst have rated the stock as Strong Buy, 11 analysts said it's a Buy, 6 rated the stock as Hold, 0 analysts reported Underperform and 0 analysts gave their recommendations as Sell.

The business also recently declared a quarterly dividend, which was paid on Thursday, February 2nd. The ex-dividend date of this dividend was Friday, January 20th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.51%. Mr. Thomas M. Ryan is one of the biggest insider owners in CVS Health Corporation (NYSE:CVS), according to U.S. Securities and Exchange Commission (SEC) filings. CVS Health Corporation's dividend payout ratio (DPR) is presently 40.65%. If you are viewing this article on another domain, it was stolen and republished in violation of worldwide trademark and copyright laws. The original version of this story can be read at

Several research firms have recently weighed in on CVS. The highest analyst price target is $96.00, which implies a rally of 79 percent. Argus reissued a "buy" rating and issued a $85.00 price target (down previously from $120.00) on shares of CVS Health Corporation in a report on Thursday, November 10th. Analysts set a 12-month price target of $63.6 a share. There may be various price targets for a stock. The Company has 52-week high of $106.67 and 52-week low of $69.3. The stock has a consensus rating of "Buy" and an average price target of $95.47.

In other news, EVP Jonathan C. Roberts sold 61,196 shares of the firm's stock in a transaction on Thursday, February 16th. The volume of 5.63 Million shares climbed up over an trading activity of 3.02 Million shares.

  • Zachary Reyes